Benedetti & Gucer’s Cardlytics CDLX Stock Holding History

Benedetti & Gucer’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-204	Closed	-$259K	–	92
2021 Q2	$259K	Hold	204	–	–	0.23%	65
2021 Q1	$223K	Buy	+204	New	+$269K	0.21%	74

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Benedetti & Gucer's CDLX Position: Q3 2021 in Review

Benedetti & Gucer sold out of Cardlytics (CDLX) in Q3 2021, closing a stake of 204 shares — an estimated $259K sold.

Benedetti & Gucer first reported a position in CDLX in Q1 2021 and held it in 2 quarters. The position peaked at $259K in Q2 2021. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2021.

Benedetti & Gucer reported no remaining Cardlytics position as of Q3 2021 after selling out during the quarter.
Benedetti & Gucer sold 204 Cardlytics shares in Q3 2021, an estimated $259K.
Benedetti & Gucer first reported a position in Cardlytics in Q1 2021 and held it in 2 quarters.
Benedetti & Gucer's Cardlytics position peaked at $259K in Q2 2021.
164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2021.

Based on Benedetti & Gucer's 13F filing for Q3 2021, filed 5 Nov 2021.